Laser at Lumbar Acupoint on Pain and Quality of Life in Chronic Pelvic Pain

October 6 University

Status: Completed

Conditions: Pelvic Pain

Treatments: Other: non-steroidal drugs; Device: low level laser therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT05537207

P.T. REC/012/003799

Details and patient eligibility

About

To investigate the effect of low-level laser at lumbar sensitized acupoint on pain perception in chronic pelvic pain. BACKGROUND: chronic pelvic pain is one of the serious problems in the female, resulting in pain and less physical activity.

Full description

Thirty six females with chronic pelvic pain will participate in this study. The patients will randomly be divided into two equal groups; the control group will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as will described by their gynecologist. and the study group received the same treatment and low-level laser at lumbar sensitized Acupoint, three times per week for four weeks. The evaluation methods by visual analogue scale (VAS), pain sensitivity was evaluated by measuring mean values of pressure pain thresholds (PPT) using a Pressure Algometer, while the quality of life was evaluated by the 12-Item Short-Form Health Survey (SF-12) before and after the treatment

Enrollment: 36 patients

Sex: Female

Ages: 25 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Thirty six female with chronic pelvic pain

  • Their age ranged from 25 to 40 years old.
  • With the maximum parity number three.
  • Their body mass index (BMI) (20:29.9) kg/m2.
  • their pain score on the Visual Analog Scale (VAS) above 4 cm
  • Thirty-six married women diagnosed with chronic pelvic pain (CPP)
  • with a prior history of treatment for pelvic inflammatory disease (PID)
  • women with periodic lower abdominal or pelvic pain for at least six months and met -- the clinical diagnostic criteria for PID based on the presence of all three major criteria: lower abdominal tenderness, cervical motion tenderness, and bilateral adnexal tenderness
  • at least one minor supporting criterion: oral temperature >38.3°C (101 °F), mucopurulent cervical discharge or cervical friability, abundant WBCs on saline microscopy of vaginal fluid, elevated ESR and/or CRP, or laboratory-confirmed cervical infection with N.

gonorrhoeae or C. trachomatis

Exclusion criteria

• Any difficulty to communicate or understanding program instructions
• any other conditions that caused pain (for example fibromyalgia and arthritis)
• any psychiatric or cognitive symptoms
• any other musculoskeletal disorders or neurologic diseases
• any other conditions causing pelvic pain (e.g., fibromyalgia, arthritis), history of musculoskeletal or neurological diseases affecting the lower extremities and spine (such as lumbar disc herniation), acute pelvic inflammatory disease (PID), pregnancy or lactation, tumors, pelvic congestion, tuberculous PID, endometriosis, adenomyosis, gynecological tumors, or other gyneco-logical conditions that could contribute to chronic pelvic pain (CPP).
• any issues at acupoint sites (such as ulcers or skin conditions); impairments in other systems that could lead to pelvic and lumbosacral pain (e.g., digestive, motor, or urinary issues)
• severe systemic illnesses affecting the hematologic, digestive, urinary, or cardiovascular systems
• mental illness; cognitive deterioration
• immune-compromising diseases (such as diabetes or HIV/AIDS); and contraindications to NSAIDs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

36 participants in 2 patient groups

study group

Experimental group

Description:

low level laser therapy (LLLT) on the acupuncture points.in addition to non-steroidal anti-inflammatory drugs

Treatment:

Device: low level laser therapy

Other: non-steroidal drugs

control group

Experimental group

Description:

All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as will be described by their gynecologist.

Treatment:

Other: non-steroidal drugs